A multi-centric double-blind randomized homoeopathic pathogenetic trial of Gymnema sylvestre

Goutam Rakshit; JP Singh; SD Pathak; Ch Kishan Banoth; PK Chandra; Rajpal; Sujata Kumari Choudhury; Vinay Kr Singh

doi:10.4103/0974-7168.114270

Users Online:198

ORIGINAL ARTICLE

Year : 2013 | Volume : 7 | Issue : 1 | Page : 9-21

A multi-centric double-blind randomized homoeopathic pathogenetic trial of Gymnema sylvestre

Goutam Rakshit¹, JP Singh², SD Pathak², Ch Kishan Banoth³, PK Chandra⁴, Rajpal⁵, Sujata Kumari Choudhury¹, Vinay Kr Singh¹
¹ Drug Proving Unit, Extension Unit of RRI (H), Puri, Homoeopathic Medical College and Hospital, Bhubaneswar, Odisha, India
² Homoeopathic Drug Research Institute, Lucknow, Uttar Pradesh, India
³ Regional Research Institute (H), Gudivada, Andhra Pradesh, India
⁴ Drug Proving Research Unit, Kolkata, West Bengal, India
⁵ Central Council for Research in Homoeopathy, New Delhi, India

Correspondence Address:
Goutam Rakshit
Drug Proving Unit, Extension Unit of RRI (H), Puri, Dr. Abhin Chandra Homoeopathic Medical College and Hospital, Unit III, Kharvel Nagar, Bhubaneswar - 751 001, Odisha
India

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/0974-7168.114270

Objective: To elicit the pathogenetic response of Gymnema sylvestre in homoeopathic potencies on apparently healthy human volunteers. Methodology: Gymnema sylvestre was proved by the Central Council for Research in Homoeopathy through double-blind placebo-controlled method. The study was carried out at four centers. The drug was proved in two potencies (6C and 30C) on 63 apparently healthy volunteers who were selected after conducting pre-trial medical examination by the medical specialists and routine laboratory investigations. In the first phase volunteers were given 56 doses (04 doses per day for 14 days) of placebo. In the next two phases 56 doses (04 doses per day for 14 days) of each potency or placebo were consumed. The symptoms generated during the trial period were noted by the volunteers and elaborated by the proving masters. The data obtained from all the four centers was compiled at proving-cum-data processing cell at CCRH headquarters after decoding. Results: Out of 37 provers who were on actual drug trial, 16 manifested symptoms. The drug was able to produce symptoms in each potency in most of the parts of the body. Conclusion: The pathogenetic responses elicited during the drug proving trial expand the scope of use of the drug Gymnema sylvestre and will benefit the research scholars and clinicians. The generated symptoms of the drug will carry more meaning when verified clinically.

[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	12417

Printed	279

Emailed	0

PDF Downloaded	1003

Comments	[Add]

Cited by others	3